ערך בספרים למניה: Can-Fite (CANF)

The book value per share for Can-Fite BioPharma (CANF) on GURU.Markets reflects the business's macro resilience, where the parameter value equals 2.28. The non-cyclical demand for oncology drugs protects capital from economic downturns. However, the costs associated with final testing for psoriasis and liver cancer drugs force the company to conduct secondary offerings. This results in the creation of a scientific ecosystem through the targeting of adenosine receptors.

Can-Fite BioPharma (CANF) focuses on developing innovative drugs for cancer and psoriasis that target adenosine receptors. The BVPS trend captures the daily change in the difference between total assets and liabilities per share, allowing investors to differentiate strategic resource accumulation from capital stagnation, which is critical for assessing the fundamental value of the business during an active growth phase.